

Supplementary information

Digital endpoints in clinical trials: building the business case for systematic adoption

In the format provided by the authors and unedited

Acknowledgements

This work presents the effort of a larger precompetitive team who joined forces to “[Build the Business Case for Digital Endpoints](#)”, hosted by the Digital Medicine Society’s Digital Health Measurement Collaborative Community ([DATAcc](#)). We acknowledge the crucial contributions of (in alphabetical order):

Adam Teed (Sama Therapeutics), Aimee Degaetano (Eastern Virginia Medical School), Caroline Curie (Verily Life Sciences), David Suendermann-Oeft (Modality.AI), Dudley Tabakin (VivoSense), Elena S. Izmailova (Koneksa Health), Greta Kreuzer (Cosinuss), Hao Zhang (Mitsubishi Tanabe Pharma), Hiromasa Mori (Koneksa Health), Lauren Alani (Seuss+), Lysbeth Floden (Evinova), Joseph DiMasi (Tufts Center for the Study of Drug Development), Megan Leonard (Exponent Sciences), Michael Weber (Cosinuss), Michel Valstar (Blueskeye AI), Milos Todorovic (Analog Devices), Nabil Mir (University of Chicago Medical School), Priyanka Nagasubramanian (The Ottawa Hospital), Sakshi Sardar (Critical Path Institute), Robin Mischa van Stokkum (TNO Health & Work), Seema Dadhani (Imperial College London), Shobi Ahmed (Sama Therapeutics), Stephen Ruhmel (Sanofi Pharmaceuticals), Steven Kreuzer (Exponent Sciences), Szczepan W. Baran (Baran Cafe), Vikram Ramanarayanan (Modality.AI), Willem van den Brink (TNO Health & Work), and Yang Liu (Chugai Pharmaceutical).

Supplemental references

- [Digital Endpoints Value Framework](#)
- [Case Study Catalog](#) associated with the Digital Endpoints Value Framework
- [Digital Endpoints ROI Calculator](#)